Once diagnosed with Parkinson’s disease, most patients can expect a stable and active lifestyle for up to a decade—but new drugs could lengthen that period. This program follows five volunteers in the clinical trial of MitoQ, a medicine designed to slow the ailment’s progress. Viewers are taken through the yearlong, double-blind placebo-controlled study, in which each volunteer performs a daily regimen of physical and mental exercise while his or her symptom progression is closely monitored. Interviews feature Dr. Barry Snow, the neurologist in charge of the trial, and Ken Taylor, CEO of Antipodean Pharmaceuticals, which makes and markets MitoQ. (45 minutes)